Dr. Alan Marvin Keller, MD

Dr. Keller practices at Oklahoma Cancer Specialists and Research Institute in Tulsa, Oklahoma.

Dr. Keller's NPI, 1386696011, was assigned on May 17, 2006. Dr. Keller graduated from OU College of Medicine in 1973. Dr. Keller holds Oklahoma license 11735.

Dr. Keller's primary practice is Oklahoma Cancer Specialists and Research Institute, at 12697 E 51st St, Tulsa, OK 74146 in Tulsa County. The practice phone is (918) 505-3200.

Dr. Keller's primary practice is Oklahoma Cancer Specialists and Research Institute in Tulsa, Oklahoma. The medical group on file is Oklahoma Cancer Specialists and Research Institute. Dmand AI also links Dr. Keller to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Keller practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Keller's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Keller is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Keller's licenses on file in 3 states: Oklahoma, Colorado and Maryland.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, lung cancer, lymphoma, multiple myeloma and neutropenia among the conditions Dr. Keller treats.

CMS data shows 44 Medicare services from Dr. Keller across 2 procedure codes in 2024, all of them office visits, for 44 Medicare patients. Medicare paid $4,987 for them. Every service was in an office.

CMS counts 44 Medicare patients who saw Dr. Keller in 2024. The largest group is 75 to 84, with 24 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.54, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Keller's median patient age at 69, with 69% women.

In 2024, Dr. Keller wrote 39 Medicare Part D claims. 85% of them were for generic drugs. They cover 5 drugs, with $21,587 in total drug cost. In 2022, CMS named 1,311 claims across 40 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Keller for performance year 2024, reported as part of a group. Dr. Keller accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 8 papers to Dr. Keller in 2009. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Amsacrine and Cytarabine. Dr. Keller has published most often in J Clin Oncol. Dr. Keller's most frequent co-authors are Stephen A. Bernard, MD, Peter D. Eisenberg, MD and Louis Fehrenbacher, MD.

Dmand AI links Dr. Keller to 9 clinical trials, 4 of them phase 3 studies. Conditions studied include Neurotoxicity Syndromes, Poisoning and Carcinoma, Hepatocellular. Alliance for Clinical Trials in Oncology sponsors the most, 8. Open Payments lists research payments to Dr. Keller that name 1 trial.

CMS Open Payments shows 41 general payments to Dr. Keller from 21 drug and device companies from 2016 to 2023. Food and beverage make up the largest share, 83% of the total. Bristol-Myers Squibb Company paid the most, $159. It also lists 1 research payment totaling $110 in 2016, naming 1 clinical trial.

Dmand AI lists 1 award for Dr. Keller, most recently CMS Stage 1 EHR in 2013.

Dr. Keller graduated from OU College of Medicine in 1973. Dr. Keller is a member of ASCO.

Dr. Keller is in network with 11 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.